Cellex is generally applied across domains where additional symptomatic support is needed in the context of cerebrovascular diseases (conditions affecting the brain's blood supply). The therapeutic profile is commonly used in clinical settings that involve acute or unstable symptom patterns associated with these conditions.

The medication is commonly used to help address symptom clusters that may become intense or disruptive, applicable in conditions characterized by the acute period and early rehabilitation phase of severe cerebral circulation disorders (like stroke), and is relevant for easing the persistent effects of chronic cerebral ischemia and related mild to moderate neurocognitive disorders.

“The use may help patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort during periods of heightened symptoms.”

Support During Acute Neurological Events

Cellex is commonly used as a component of complex therapy during the acute period and early rehabilitation phase following severe cerebral circulation disorders. This application is relevant when supportive symptom management is appropriate in scenarios where symptoms create noticeable physiological strain. The therapy is generally applied when supportive symptom management is appropriate, and may assist with maintaining functional stability during difficult episodes.

Managing Chronic Ischemia and Cognitive Symptoms

For patients dealing with the persistent effects of chronic cerebral ischemia, Cellex is commonly used to help with mild and moderate neurocognitive disorders of vascular origin. This therapeutic domain is relevant for managing symptoms that interfere with daily comfort, such as those related to impaired learning and memory processes. The use may help patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort during periods of heightened symptoms.

---

Quick Fact: Symptomatic Support

Symptom Domain	General Benefit Provided
Cognitive Deficits (e.g., memory, learning)	Helps maintain a sense of stability when symptoms are more noticeable.
Acute Functional Strain (Post-Stroke)	May assist with maintaining functional stability.

Who can and cannot use Cellex?

Cellex is officially designated for use by adult patients aged 18 years and older. The regulatory documentation strictly defines specific populations and clinical conditions for whom the medicine is prohibited or restricted.

The drug is contraindicated for individuals under 18 years of age. This age-based restriction is in place due to the insufficiency of clinical data regarding its safety and efficacy in pediatric and adolescent populations.

---

Absolute Contraindications

Cellex must not be used if the patient has a known hypersensitivity to any of its components or if they present with the following specific neurological or psychiatric conditions:

• Epilepsy.
• Manic Psychosis.
• Productive Delusions or Delirium.

Furthermore, due to the absence of corresponding studies, the medicine is contraindicated for women during pregnancy and while breastfeeding (lactation).

---

Conditional Restriction

The official labeling requires that Cellex be prescribed with caution to patients who have a documented history of allergic reactions to preparations of a protein-peptide nature.

Cellex Interactions with other medicines and products

The official regulatory information for Cellex describes interactions based primarily on pharmacodynamic effects within the central nervous system (CNS). The prescribing information does not list formal contraindications due to drug interaction risk, nor does it document any pharmacokinetic interactions, such as those mediated by Cytochrome P450 enzymes or drug transporters, that would alter Cellex's plasma exposure.

The documented interaction profile is summarized by the following official statements regarding co-administration of medicinal products and substances:

• Psychostimulant Drugs and Alcohol: Co-administration with psychostimulant drugs or the substance alcohol is officially documented. This combination may result in the occurrence of heightened CNS effects, specifically psychomotor agitation and sleep disorders.
• CNS Depressant Medications: Co-administration with certain CNS depressants, including functional categories such as anesthetics, tranquilizers, and neuroleptics, may lead to a reduction in the activity or efficacy of the co-administered CNS depressant medication.

Classification	Official Regulatory Status
Interaction Severity Classification	Use-with-Caution (due to documented pharmacodynamic effects); not Contraindicated.
Timing-based Separation Rules	None documented. The official label does not specify mandatory time spacing between doses.
Population-Specific Interaction Notes	None documented. No specific warnings are provided for populations such as the elderly or those with hepatic or renal impairment.

This structure is entirely derived from the National Medicines Authority Labeling and defines constraints according to functional pharmacodynamic outcomes, without involving a discussion of benefits, therapeutic uses, or general safety narratives.

The mechanism of the Cellex system, utilizing the drug Methoxsalen and UVA light for Extracorporeal Photopheresis (ECP), initiates a multi-step pharmacodynamic cascade leading to systemic immune system modulation.

Targeted DNA Damage and Apoptosis

Methoxsalen, a DNA intercalating agent, targets the DNA of isolated circulating leukocytes, primarily T-cells, ex vivo. Upon exposure to UVA light, the drug becomes photo-activated, forming covalent crosslinks with pyrimidine bases in the DNA strands. This substantial DNA damage inhibits cell proliferation and rapidly induces a controlled cellular self-destruction process known as apoptosis in the treated T-cell population.

Induction of Systemic Immune Tolerance

Reinfusion of the apoptotic leukocytes introduces cells recognized as cellular debris by the body. Specialized Antigen-Presenting Cells (APCs) phagocytose (engulf) these cells, initiating an altered signaling cascade. This uptake promotes a shift in the immune environment by facilitating the differentiation and expansion of Regulatory T-cells (Tregs).

Modulation of Clonal T-Cell Activity

These collective molecular and cellular actions ultimately influence the physiological domain of T-cell regulation. The mechanism limits T-cell clonal expansion and drives a systemic immune system modulation that influences the overall activity of immune responses.

How to Use Cellex

The administration of Cellex is based on specific parameters detailing the route, preparation steps, daily dosage, and cyclic treatment schedule.

---

Administration Route and Preparation

Cellex is formulated exclusively as a sterile solution intended for subcutaneous injection (п/к). The preparation involves a specific step: the prescribed volume is drawn into a syringe and subsequently filtered through a sterile syringe filter (0.22 mu m pore diameter). This specific filtration component, which is supplied in the drug's packaging, is used for its administration. Following filtration, any air bubbles are expelled from the syringe. There is no specified required relationship between administration and meals or a particular time of day.

---

Dosing Schedule and Treatment Cycles

For adult patients, the standard daily dose of Cellex is within the range of 0.1 mg to 0.2 mg. The medication is administered once daily (1 раз/сут). Use is structured into a defined treatment course lasting for 10 days. If a subsequent course is required, a 10-day break is observed following the completion of the previous cycle before a new course is initiated.

---

Population-Specific Use

The use of Cellex is restricted in individuals under 18 years of age. This limitation exists because clinical studies have not been conducted within the pediatric population to establish usage guidelines for this age group. There are no provided dose adjustments for older adults or patients with hepatic or renal impairment.

Recent Clinical Evidence Overview

Research on Cellex involves evaluating its role in different disease contexts, particularly where immune modulation is a key factor. Studies primarily focus on the Therakos Cellex Photopheresis System, a device used for extracorporeal photopheresis (ECP) in conjunction with a photoactive drug like methoxsalen.

ECP with the Cellex system is a method for treating Cutaneous T-Cell Lymphoma (CTCL) skin manifestations that have not responded to other forms of treatment, and Systemic Sclerosis (SSc). Research also explored the therapy's profile in other immune-mediated conditions.

---

Key Study Findings

Cutaneous T-Cell Lymphoma (CTCL)

Multiple multicenter, single-arm, open-label trials assessed the efficacy of ECP for CTCL skin manifestations. Success was often measured by a reduction in the skin score (e.g., ge 25%) maintained over a specific period. These studies involved patients with mycosis fungoides and Sézary syndrome.

Systemic Sclerosis (SSc)

Studies in SSc patients have assessed skin score improvement and changes in measures like oral aperture (mouth opening) and hand closure after treatment periods of six to ten months. Research has reported statistically significant improvements in these measures compared to baseline.

---

Special Populations and Safety

Studies have evaluated the Cellex ECP system in pediatric and young adult patients with steroid-refractory acute Graft-versus-Host Disease (aGvHD). Safety monitoring in these trials tracked adverse events, with most serious events considered unrelated to the treatment system itself.

Safety data collected through clinical trials and post-marketing surveillance primarily note adverse events related to the extracorporeal circulation process, such as hypotension secondary to blood volume changes, and transient pyretic reactions (fever) in the hours following reinfusion of treated white blood cells.

Key Studies & References

1. Safety and effectiveness of extracorporeal photopheresis for steroid-refractory acute graft-versus-host disease in pediatric patients: A single center study

Common questions about Cellex (FAQ)

---

Q: How should I dispose of used Cellex ampoules or syringes?

According to the official product information, any unused or expired Cellex and its associated materials must not be discarded in household trash or down the drain. The official guidance specifies that disposal should be in accordance with local regulations for pharmaceutical waste. This requirement indicates the necessity of a specialized disposal method, such as those used for other pharmaceutical waste, for the used ampoules and syringes.

---

Q: Can Cellex be taken with food?

The official instructions for the administration of Cellex do not specify a required relationship between taking the injection and meals. Therefore, official instructions do not mandate a specific time (before, during, or after a meal) for administration.

Official Storage Requirements

Cellex solution for subcutaneous injection must be stored strictly within the mandated cold-chain temperature range of 2 C to 8 C. It is essential to protect the medicine from light, which is supported by keeping the ampoules in the original packaging. The medication must not be frozen (stored below 2 C) or exposed to temperatures above 8 C. When stored under these specific refrigerated and light-protected conditions, the product maintains a 2-year shelf-life, and it must not be used after the expiration date on the package.

Child Safety and Disposal

Consistent with regulatory requirements, Cellex must be stored in a location that is inaccessible to children. Any unused or expired Cellex ampoules and associated materials should be disposed of in accordance with local regulations for pharmaceutical waste. Disposal instructions in official labeling do not permit discarding the product in household trash or down the drain.